title: Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.
abstract: We studied the roles of autologous (A) and allogeneic (allo) stem cell transplantation (SCT) in the treatment of 134 patients with T cell lymphoma (TCL) at our center. For frontline SCT, 58 patients were studied. The 4-year overall survival (OS) rates for ASCT (n = 47; median age, 49 years) and alloSCT (n = 11; median age, 55 years) groups were 76% and 54%, respectively (P > .05). The 4-year OS rates for first complete remission (CR1) patients were 84% and 83%, respectively. For SCT for relapsed disease, 76 patients were studied (41 with ASCT and 35 with alloSCT). The 4-year OS rates were 50% and 36% for ASCT and alloSCT patients with chemosensitive disease, respectively (P > .05). Those who were in CR2 and CR3 had 4-year OS rates of 59% and 53%, respectively. Similar results were also observed in patients with refractory disease (29% and 35%, respectively). These data suggest that a pre-SCT CR is associated with improved outcomes in TCL patients after SCT. Considering the 84% 4-year OS rates in CR1 patients and the unpredictable responses in patients with relapsed disease, we favor the use of ASCT as consolidation therapy after CR1. AlloSCT did not result in a superior outcome compared with ASCT.
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Amer
authors: A
authors: Beitinjaneh
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Rima M
authors: RM
authors: Saliba
authors: Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: L Jeffrey
authors: LJ
authors: Medeiros
authors: Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Francesco
authors: F
authors: Turturro
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Gabriela
authors: G
authors: Rondon
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Martin
authors: M
authors: Korbling
authors: Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Luis
authors: L
authors: Fayad
authors: Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Michelle A
authors: MA
authors: Fanale
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Amin M
authors: AM
authors: Alousi
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Paolo
authors: P
authors: Anderlini
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Oran
authors: O
authors: Betul
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Uday R
authors: UR
authors: Popat
authors: Department of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Philadelphia, Pennsylvania.
authors: Barbara
authors: B
authors: Pro
authors: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ikhouri@mdanderson.org.
authors: Issa F
authors: IF
authors: Khouri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D064591:Allografts; D064592:Autografts; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016399:Lymphoma, T-Cell / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D015996:Survival Rate
keywords: Lymphoma; Stem cell transplantation; T cell
references: J Clin Oncol. 2013 Sep 1;31(25):3100-9
references: 23897963
references: J Clin Oncol. 1999 Apr;17(4):1244
references: 10561185
references: J Clin Oncol. 2001 Sep 1;19(17):3766-70
references: 11533100
references: Blood. 2004 Apr 1;103(7):2474-9
references: 14645001
references: Cancer. 2005 May 15;103(10):2091-8
references: 15816054
references: Leukemia. 2006 Sep;20(9):1533-8
references: 16871285
references: Ann Oncol. 2008 May;19(5):958-63
references: 18303032
references: J Clin Oncol. 2008 May 10;26(14):2264-71
references: 18390969
references: Blood. 2008 Jun 15;111(12):5496-504
references: 18385450
references: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references: 18626005
references: J Clin Oncol. 2009 Jan 1;27(1):106-13
references: 19029417
references: Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25
references: 19135950
references: Br J Haematol. 2010 Jul;150(2):170-8
references: 20507311
references: Ann Oncol. 2011 Feb;22(2):397-404
references: 20631009
references: J Clin Oncol. 2011 Mar 20;29(9):1182-9
references: 21245435
references: Blood. 2011 Jun 23;117(25):6756-67
references: 21493798
references: Ann Oncol. 2011 Jul;22(7):1608-13
references: 21252059
references: J Clin Oncol. 2012 Feb 20;30(6):631-6
references: 22271479
references: Leukemia. 2012 Mar;26(3):520-6
references: 21904377
references: J Clin Oncol. 2012 Jun 20;30(18):2190-6
references: 22614995
references: J Clin Oncol. 2012 Sep 1;30(25):3093-9
references: 22851556
references: J Clin Oncol. 2013 Jun 1;31(16):1970-6
references: 23610113
references: J Clin Oncol. 2013 Jun 1;31(16):1922-7
references: 23630204